Off-label use of emicizumab in persons with acquired haemophilia A and von Willebrand disease: A scoping review of the literature.
Vinay Mathew ThomasMouhamed Yazan Abou-IsmailMing Y LimPublished in: Haemophilia : the official journal of the World Federation of Hemophilia (2021)
Based on published case reports and case series, emicizumab appears to be an effective haemostatic therapy for AHA and VWD. Larger confirmatory clinical trials are needed to confirm these findings.